Literature DB >> 19389503

Genomic amplification of the human telomerase RNA gene for differential diagnosis of cervical disorders.

Zheng Tu1, Aipeng Zhang, Ruifang Wu, Jing Jiang, Yali Li, Na Wulan, Jingran Li, Yongmei Zhang, Yibing Li, Zhong Chen, Lihui Wei.   

Abstract

To evaluate genomic amplification of the human telomerase RNA gene (TERC) as a supportive approach to cytopathology or histopathology in diagnosis of low-grade and high-grade uterine cervical lesions, 1,033 Chinese women at three medical centers had liquid-based thin-layer cytopathologic examination and TERC detection by fluorescence in situ hybridization (FISH). Human papillomavirus DNA testing, colposcopy with or without biopsy, and histopathologic examination were conducted as needed. In cytopathologic examination, genomic amplification of TERC was found in 30 of 659 (4.6%) normal or benign cellular changes; in 23 of 170 (13.5%) atypical squamous cells of undetermined significance (ASCUS); in 8 of 28 (28.6%) atypical squamous cells with high-grade squamous intraepithelial lesion possible (ASC-H); and in 26 of 103 (25.2%) low-grade (LSIL) and 64 of 73 (87.7%) high-grade (HSIL) squamous intraepithelial lesions; with pairwise significant difference (P< 0.05) in each, except ASC-H and LSIL (chi(2) = 0.127, P = 0.72). In histopathologic examination, TERC was amplified in 28 of 671 (4.2%) normal, inflammatory, or wart cases; in 17 of 233 (7.3%) cervical intraepithelial neoplasia grade 1 cases (CIN 1); in 27 of 39 (69.2%) CIN 2 cases; in 57 of 67 (85.1%) CIN 3 cases; and in 22 of 23 (95.7%) cervical cancer cases; with pairwise significant difference in each (P < 0.05). The number of cells with abnormal signals increased and the abnormal signal patterns were diversified with increasing severity of cervical dysplasia. FISH detection of TERC amplification may provide an effective, noninvasive approach in conjunction with cytopathologic or histopathologic evaluation for differential diagnosis of low- and high-grade cervical disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389503     DOI: 10.1016/j.cancergencyto.2009.01.004

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

Review 1.  Telomerase and the process of cervical carcinogenesis.

Authors:  M Nachajova; D Brany; D Dvorska
Journal:  Tumour Biol       Date:  2015-08-30

2.  Detection of TERC amplification in cervical epithelial cells for the diagnosis of high-grade cervical lesions and invasive cancer: a multicenter study in China.

Authors:  Jing Jiang; Li-Hui Wei; Ya-Li Li; Rui-Fang Wu; Xing Xie; You-Ji Feng; Guo Zhang; Chao Zhao; Yun Zhao; Zhong Chen
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

3.  The significant diagnostic value of human telomerase RNA component (hTERC) gene detection in high-grade cervical lesions and invasive cancer.

Authors:  Xiaobin Wang; Jia Liu; Hong Xi; Liping Cai
Journal:  Tumour Biol       Date:  2014-04-16

4.  Genomic amplification patterns of human telomerase RNA gene and C-MYC in liquid-based cytological specimens used for the detection of high-grade cervical intraepithelial neoplasia.

Authors:  Shaomin Chen; Ziyan Yang; Yun Zhang; Yunbo Qiao; Baoxia Cui; Youzhong Zhang; Beihua Kong
Journal:  Diagn Pathol       Date:  2012-04-13       Impact factor: 2.644

5.  Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx.

Authors:  Yu Liu; Xiao-li Dong; Cheng Tian; Hong-gang Liu
Journal:  Diagn Pathol       Date:  2012-03-30       Impact factor: 2.644

6.  Increased expression of long non-coding RNA XIST predicts favorable prognosis of cervical squamous cell carcinoma subsequent to definitive chemoradiation therapy.

Authors:  Reiko Kobayashi; Ryu Miyagawa; Hideomi Yamashita; Teppei Morikawa; Kae Okuma; Masashi Fukayama; Kuni Ohtomo; Keiichi Nakagawa
Journal:  Oncol Lett       Date:  2016-08-26       Impact factor: 2.967

7.  3q26 amplification is an effective negative triage test for LSIL: a historical prospective study.

Authors:  Erica R Heitmann; Kamani M Lankachandra; Jeff Wall; George D Harris; Hollie J McKinney; G Reza Jalali; Yogita Verma; Eric Kershnar; Michael W Kilpatrick; Petros Tsipouras; Diane M Harper
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.